Bakuchiol perturbs purine metabolism and ABC transporter pathways in Streptococcus agalactiae, possibly affecting S. agalactiae-induced mastitis
- 1Key Laboratory of Biochemistry and Molecular Biology in Universities of Shandong Province, Weifang University
- 2School of Pharmacy, Lanzhou University
- 3Key Laboratory of Vector Biology and Pathogen Control of Zhejiang Province, College of Life Science, Huzhou University
Abstract
Objective: To evaluate the bacteriostatic effect of Bakuchiol (Bak) against Streptococcus agalactiae , explored its antibacterial mechanism in vitro , and investigated its in-vivo therapeutic activity in a mouse mastitis model.
Methods: The Oxford cup assay was performed to test its inhibitory activity on S. agalactiae . Scanning electron microscopy and qPCR were employed to unravel the in-vitro molecular mechanism of Bak. Metabolomics was conducted to assess the impact of Bak on bacterial metabolites. A S. agalactiae -induced mouse mastitis model was constructed, and its therapeutic efficacy in mice was evaluated via histopathological sections and detection of inflammatory cytokine (IL-6, IL-8, IL-1β and TNF-α) expression.
Results: Among 24 natural small-molecule phenolic compounds, Bak exhibited favorable antibacterial activity against Streptococcus agalactiae . Mechanistic studies revealed that Bak significantly inhibited the production of virulence factors and the expression of virulence genes. Notably, it suppressed biofilm formation by disrupting initial adhesion, eliminating mature biofilms, and reducing biofilm metabolism and extracellular polymer production. Untargeted metabolomics analysis revealed that Bak might produce antibacterial activity through significant disruption of purine metabolism and ABC transport-associated metabolic pathways in S. agalactiae . Acute toxicity studies indicated that Bak exhibited low toxicity. In a mouse mastitis model, Bak significantly improved mastitis by mitigating tissue damage, and downregulating pro-inflammatory cytokine levels.
Conclusion: Bak attenuated S. agalactiae pathogenicity through a multi-target mechanism, positioning it as a potential therapeutic candidate for bacterial mastitis.
Related
- A closed genome of Streptococcus agalactiae ST347/II reveals a composite integrative element coupling nisin P biosynthesis to erm(B) and tet(O) in Dominican group B Streptococcus
- Type VII secretion system promotes Streptococcus agalactiae virulence through magnesium acquisition and capsule maintenance
- Comparative genomic and phenotypic analysis of human- and dairy cattle -derived Streptococcus agalactiae reveals potential cross-species infection capability.
- Overexpression of endoplasmic reticulum acetyl-CoA transporter AT-1 alters neuronal metabolism, growth, and synaptic activity
- PqqU (PA2289) is the primary PQQ transporter in Pseudomonas aeruginosa and links carbon metabolism to iron homeostasis
BibTeX
@article{wang2026bakuchiol,
title = {{Bakuchiol perturbs purine metabolism and ABC transporter pathways in Streptococcus agalactiae, possibly affecting S. agalactiae-induced mastitis}},
author = {Rui Wang and Ya-Rui Jin and Wei-Qi Jiang and Jun-Xia An and Guo-Liang Mou and Li-Jing Zhang and Ying-Qian Liu and Zhi-Jun Zhang and Shao-Yong Zhang},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1961106},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1961106/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Bakuchiol perturbs purine metabolism and ABC transporter pathways in Streptococcus agalactiae, possibly affecting S. agalactiae-induced mastitis
AU - Rui Wang
AU - Ya-Rui Jin
AU - Wei-Qi Jiang
AU - Jun-Xia An
AU - Guo-Liang Mou
AU - Li-Jing Zhang
AU - Ying-Qian Liu
AU - Zhi-Jun Zhang
AU - Shao-Yong Zhang
PY - 2026
DA - 2026/10/28
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1961106
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1961106/full
AB - Objective: To evaluate the bacteriostatic effect of Bakuchiol (Bak) against Streptococcus agalactiae , explored its antibacterial mechanism in vitro , and investigated its in-vivo therapeutic activity in a mouse mastitis model. Methods: The Oxford cup assay was performed to test its inhibitory activity on S. agalactiae . Scanning electron microscopy and qPCR were employed to unravel the in-vitro molecular mechanism of Bak. Metabolomics was conducted to assess the impact of Bak on bacterial metabolites. A S. agalactiae -induced mouse mastitis model was constructed, and its therapeutic efficacy in mice was evaluated via histopathological sections and detection of inflammatory cytokine (IL-6, IL-8, IL-1β and TNF-α) expression. Results: Among 24 natural small-molecule phenolic compounds, Bak exhibited favorable antibacterial activity against Streptococcus agalactiae . Mechanistic studies revealed that Bak significantly inhibited the production of virulence factors and the expression of virulence genes. Notably, it suppressed biofilm formation by disrupting initial adhesion, eliminating mature biofilms, and reducing biofilm metabolism and extracellular polymer production. Untargeted metabolomics analysis revealed that Bak might produce antibacterial activity through significant disruption of purine metabolism and ABC transport-associated metabolic pathways in S. agalactiae . Acute toxicity studies indicated that Bak exhibited low toxicity. In a mouse mastitis model, Bak significantly improved mastitis by mitigating tissue damage, and downregulating pro-inflammatory cytokine levels. Conclusion: Bak attenuated S. agalactiae pathogenicity through a multi-target mechanism, positioning it as a potential therapeutic candidate for bacterial mastitis.
SN - 1664-302X
ER -